250 related articles for article (PubMed ID: 24616427)
1. HspX vaccination and role in virulence in the guinea pig model of tuberculosis.
Wieczorek AE; Troudt JL; Knabenbauer P; Taylor J; Pavlicek RL; Karls R; Hess A; Davidson RM; Strong M; Bielefeldt-Ohmann H; Izzo AA; Dobos KM
Pathog Dis; 2014 Aug; 71(3):315-25. PubMed ID: 24616427
[TBL] [Abstract][Full Text] [Related]
2. In vivo persistence and protective efficacy of the bacille Calmette Guerin vaccine overexpressing the HspX latency antigen.
Spratt JM; Britton WJ; Triccas JA
Bioeng Bugs; 2010; 1(1):61-5. PubMed ID: 21327127
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine expressing a fusion protein of Ag85B-Esat6-HspX in mice.
Yuan W; Dong N; Zhang L; Liu J; Lin S; Xiang Z; Qiao H; Tong W; Qin C
Vaccine; 2012 Mar; 30(14):2490-7. PubMed ID: 21704108
[TBL] [Abstract][Full Text] [Related]
4. HspX-mediated protection against tuberculosis depends on its chaperoning of a mycobacterial molecule.
Taylor JL; Wieczorek A; Keyser AR; Grover A; Flinkstrom R; Karls RK; Bielefeldt-Ohmann H; Dobos KM; Izzo AA
Immunol Cell Biol; 2012 Nov; 90(10):945-54. PubMed ID: 22801575
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and protective efficacy of a fusion protein vaccine consisting of antigen Ag85B and HspX against Mycobacterium tuberculosis infection in mice.
Li Q; Yu H; Zhang Y; Wang B; Jiang W; Da Z; Xian Q; Wang Y; Liu X; Zhu B
Scand J Immunol; 2011 Jun; 73(6):568-76. PubMed ID: 21323695
[TBL] [Abstract][Full Text] [Related]
6. Fused Mycobacterium tuberculosis multi-stage immunogens with an Fc-delivery system as a promising approach for the development of a tuberculosis vaccine.
Mosavat A; Soleimanpour S; Farsiani H; Sadeghian H; Ghazvini K; Sankian M; Jamehdar SA; Rezaee SA
Infect Genet Evol; 2016 Apr; 39():163-172. PubMed ID: 26835592
[TBL] [Abstract][Full Text] [Related]
7. Construction and evaluation of a multistage Mycobacterium tuberculosis subunit vaccine candidate Mtb10.4-HspX.
Niu H; Hu L; Li Q; Da Z; Wang B; Tang K; Xin Q; Yu H; Zhang Y; Wang Y; Ma X; Zhu B
Vaccine; 2011 Nov; 29(51):9451-8. PubMed ID: 22024175
[TBL] [Abstract][Full Text] [Related]
8. Immunogenic potential of latency associated antigens against Mycobacterium tuberculosis.
Singh S; Saraav I; Sharma S
Vaccine; 2014 Feb; 32(6):712-6. PubMed ID: 24300592
[TBL] [Abstract][Full Text] [Related]
9. Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens.
Brodin P; Majlessi L; Brosch R; Smith D; Bancroft G; Clark S; Williams A; Leclerc C; Cole ST
J Infect Dis; 2004 Jul; 190(1):115-22. PubMed ID: 15195250
[TBL] [Abstract][Full Text] [Related]
10. Ag85b/ESAT6-CFP10 adjuvanted with aluminum/poly-IC effectively protects guinea pigs from latent mycobacterium tuberculosis infection.
Wang C; Lu J; Du W; Wang G; Li X; Shen X; Su C; Yang L; Chen B; Wang J; Xu M
Vaccine; 2019 Jul; 37(32):4477-4484. PubMed ID: 31266673
[TBL] [Abstract][Full Text] [Related]
11. A live attenuated BCG vaccine overexpressing multistage antigens Ag85B and HspX provides superior protection against Mycobacterium tuberculosis infection.
Yuan X; Teng X; Jing Y; Ma J; Tian M; Yu Q; Zhou L; Wang R; Wang W; Li L; Fan X
Appl Microbiol Biotechnol; 2015 Dec; 99(24):10587-95. PubMed ID: 26363555
[TBL] [Abstract][Full Text] [Related]
12. Microstructured liposome subunit vaccines reduce lung inflammation and bacterial load after Mycobacterium tuberculosis infection.
Trentini MM; de Oliveira FM; Gaeti MP; Batista AC; Lima EM; Kipnis A; Junqueira-Kipnis AP
Vaccine; 2014 Jul; 32(34):4324-32. PubMed ID: 24951861
[TBL] [Abstract][Full Text] [Related]
13. T-cell recognition of the HspX protein of Mycobacterium tuberculosis correlates with latent M. tuberculosis infection but not with M. bovis BCG vaccination.
Geluk A; Lin MY; van Meijgaarden KE; Leyten EM; Franken KL; Ottenhoff TH; Klein MR
Infect Immun; 2007 Jun; 75(6):2914-21. PubMed ID: 17387166
[TBL] [Abstract][Full Text] [Related]
14. A Mycobacterium tuberculosis-specific subunit vaccine that provides synergistic immunity upon co-administration with Bacillus Calmette-Guérin.
Woodworth JS; Clemmensen HS; Battey H; Dijkman K; Lindenstrøm T; Laureano RS; Taplitz R; Morgan J; Aagaard C; Rosenkrands I; Lindestam Arlehamn CS; Andersen P; Mortensen R
Nat Commun; 2021 Nov; 12(1):6658. PubMed ID: 34795205
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of immune response against Mycobacterium tuberculosis HspX antigen by incorporation of combined molecular adjuvant (CASAC).
Lew MH; Norazmi MN; Tye GJ
Mol Immunol; 2020 Jan; 117():54-64. PubMed ID: 31739193
[TBL] [Abstract][Full Text] [Related]
16. Enhanced protection against tuberculosis by vaccination with recombinant BCG over-expressing HspX protein.
Shi C; Chen L; Chen Z; Zhang Y; Zhou Z; Lu J; Fu R; Wang C; Fang Z; Fan X
Vaccine; 2010 Jul; 28(32):5237-44. PubMed ID: 20538090
[TBL] [Abstract][Full Text] [Related]
17. The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs.
Brandt L; Skeiky YA; Alderson MR; Lobet Y; Dalemans W; Turner OC; Basaraba RJ; Izzo AA; Lasco TM; Chapman PL; Reed SG; Orme IM
Infect Immun; 2004 Nov; 72(11):6622-32. PubMed ID: 15501795
[TBL] [Abstract][Full Text] [Related]
18. The development and preliminary evaluation of a new Mycobacterium tuberculosis vaccine comprising Ag85b, HspX and CFP-10:ESAT-6 fusion protein with CpG DNA and aluminum hydroxide adjuvants.
Chen L; Xu M; Wang ZY; Chen BW; Du WX; Su C; Shen XB; Zhao AH; Dong N; Wang YJ; Wang GZ
FEMS Immunol Med Microbiol; 2010 Jun; 59(1):42-52. PubMed ID: 20298499
[TBL] [Abstract][Full Text] [Related]
19. The recombinant fusion protein CFP10-ESAT6-dIFN has protective effect against tuberculosis in guinea pigs.
Permyakova NV; Belavin PA; Pirozhkova DS; Ufimtseva EG; Rozov SM; Mursalimov SR; Sidorchuk YV; Uvarova EA; Zagorskaya AA; Marenkova TV; Bannikova SV; Demidov EA; Starostin KV; Kravchenko MA; Vakhrusheva DV; Berdnikov RB; Eremeeva NI; Skornyakov SN; Peltek SE; Deineko EV
Acta Microbiol Immunol Hung; 2018 Mar; 65(1):39-58. PubMed ID: 29243495
[TBL] [Abstract][Full Text] [Related]
20. Future Path Toward TB Vaccine Development: Boosting BCG or Re-educating by a New Subunit Vaccine.
Gupta N; Garg S; Vedi S; Kunimoto DY; Kumar R; Agrawal B
Front Immunol; 2018; 9():2371. PubMed ID: 30386336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
